All Oncology News

Bortezomib maintenance was associated with lower rates of moderate-to-severe cGVHD in newly diagnosed multiple myeloma after allo-HSCT.

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial.

Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctDNA status.

Zoldonrasib produced responses and no grade 4 or 5 TRAEs in previously treated KRAS G12D–mutated NSCLC.

Daniel Johnson, MD, discusses the use of TIL therapy in melanoma, including patient selection, sequencing, timing, and emerging applications beyond skin cancer.

Roswell Park Comprehensive Cancer Center launched a trial of a new CAR T-cell therapy for AML that has relapsed or persisted despite earlier treatment.

The FDA has granted priority review to the sBLAs for pembrolizumab and subcutaneous pembrolizumab plus enfortumab vedotin in cisplatin-eligible MIBC.

Sharon Castellino, MD, MSc, discusses the significance of the FDA approval of nivolumab plus AVD for stage III/IV classical Hodgkin lymphoma.

Relapse following allo-HSCT remains frequent and represents an ongoing therapeutic challenge for patients with myelofibrosis or BP-MPNs.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

With burnout and conference attendance prevalent across the oncology community, oncology professionals strive to enact positive changes.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Gynecologic oncologists share their top data picks from SGO 2026, including ROSELLA, KEYNOTE-B96, NRG-GY019, and more.

A new model explains how genetic information is not just stored but continuously used to keep cells organized and functioning.

Dallas Gallagher, DNP, FNP-C, AOCNP, discusses individualized chemotherapy selection and the importance of a "person-first" approach to pancreatic cancer care.

Joshua Lang, MD, MS, discusses the rationale for, and design of, the MEVPRO-1 and MEVPRO-2 studies in mCRPC.

Jennifer Wargo, MD, of The University of Texas MD Anderson Cancer Center, has been elected to the 2026 class of Fellows of the American Association for Cancer Research (AACR) Academy.

Christine M. Lovly, MD, PhD, FASCO, discuses acquired resistance in EGFR-mutated NSCLC, including detection and novel approaches to address it.

Multipeptide vaccines in combination with BTK inhibitor–based regimens yielded safety and potent T-cell responses in chronic lymphocytic leukemia.

Susan Scott, MD, Julia Rotow, MD, and Enriqueta Felip, MD, PhD, debate the optimal choice of frontline regimen for EGFR-mutated NSCLC.

OPN-6602 received FDA fast track designation for relapsed/refractory multiple myeloma after at least 4 prior lines of therapy.

An sBLA seeking the approval of zenocutuzumab has been submitted to the FDA, and the agent was added to the NCCN guidelines for NRG1-positive cholangiocarcinoma.

Christian Capitini has been named the next director of the University of Wisconsin Carbone Cancer Center.

During a recent Peer Exchange, breast and lung cancer experts discussed comprehensive strategies for identifying and mitigating the AEs associated with ADCs.

Aaron Gerds, MD, details the rationale behind investigating agents targeting CALR mutations and other novel therapies in myeloproliferative neoplasms.

Alicia Morgans, MD, MPH, and Michael Schweizer, MD, discuss the phase 3 MEVPRO-1 and MEVPRO-2 trials of mevrometostat plus enzalutamide in mCRPC.

Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors.

The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.